Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aldeyra Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALDX
Nasdaq
8731
https://www.aldeyra.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aldeyra Therapeutics Inc
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
- May 14th, 2024 1:40 pm
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
- May 8th, 2024 11:00 am
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
- Apr 25th, 2024 11:00 am
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
- Apr 22nd, 2024 1:40 pm
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
- Apr 18th, 2024 11:00 am
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
- Apr 6th, 2024 10:37 am
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
- Apr 5th, 2024 1:40 pm
Health Care Roundup: Market Talk
- Apr 4th, 2024 4:36 pm
Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval
- Apr 3rd, 2024 6:58 pm
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner
- Apr 3rd, 2024 11:17 am
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
- Mar 28th, 2024 11:00 am
Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares
- Mar 13th, 2024 6:33 am
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
- Mar 6th, 2024 2:40 pm
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
- Mar 4th, 2024 2:40 pm
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
- Mar 1st, 2024 2:45 pm
5 Small Drug Stocks to Buy From a Rebounding Industry
- Feb 29th, 2024 1:53 pm
Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company
- Feb 22nd, 2024 12:35 pm
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 12:00 pm
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
- Jan 4th, 2024 12:00 pm
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
- Dec 19th, 2023 12:00 pm
Scroll